Fonny Schenck (Strategic Management Advisor) and Patrick Vidal (SVP Global Accounts) shared highlights from our 2022 Global Trends Report, including some of last year's most interesting insights pulled from our industry-leading Navigator365™ and Maturometer™ research. You can look forward to a unique snapshot of what biopharma and its HCP and payer audiences have been thinking and doing in the omnichannel space in 2022, as well as a look ahead at what to expect in 2023 and beyond. Key topics included: • Enduring shifts in HCP channel & content affinity & impact • HCP interest in & (dis)satisfaction with biopharma’s digital offerings • The competitive landscape • Future scenarios • Insights and key trends for EU5, US, LATAM & APAC Watch the recorded webinar and access the full deck here: https://rb.gy/h1qu5x

1. Proprietary and confidential information
© Across Health
1
25/04/2023
1
<business card space>
Global HCP & competitor omnichannel
trends in life sciences 2022-2023
Webinar #1 – TUESDAY 28/02
FEB to SEP 2023
Watch our recorded webinar or get access to the full slide deck >

2. Proprietary and confidential information
© Across Health
2
25/04/2023
The truly omnichannel rep is still rare..
And the trend is similar across the globe
Source: EU5 cardiologists, 2022 (n=506) & all specialists 2021 (n=8921), 2021 (n=8204)
Learn more about Navigator365™ Core

3. Proprietary and confidential information
© Across Health
3
25/04/2023
Pharma continues to underestimate the value of digital (1)
Source: 2022, EU5 specialists (n=4718) & 2022, EU Biopharma (n=217)
Read more here >

4. Proprietary and confidential information
© Across Health
4
25/04/2023
Pharma continues to underestimate the value of digital (2)
The segment with a high affinity for digital is 50% vs 44% for F2F…QUID the “no-nos”?
Source: US oncologists, 2022 (n=200)
Read more here >

5. Proprietary and confidential information
© Across Health
5
25/04/2023
Preferred time for engagement with pharma around product launch
35% expects to get pharma communications way before launch
Source: all specialists, 2022 (n=7595)
Learn more about Omnichannel Launch Excellence

6. Proprietary and confidential information
© Across Health
6
25/04/2023
The omnichannel opportunity is even higher at the payer level
Higher interest…and bigger gap vs pharma supply
…66% of
US payers
vs 53% of
US SPECs
…find pharma
digital (very)
important…
Source: US Payers, 2022 (n=167) & US specialists, 2022 (n=2060)
…and the pharma
supply gap is
bigger vs HCPs
Learn more about Navigator365™ Payer

7. Proprietary and confidential information
© Across Health
7
25/04/2023
Proprietary and confidential information
© Across Health
7
25/04/2023
Key takeaways
1. Biopharma’s urgency to invest in OCE at scale declined in 2022 while pharma satisfaction with their own
multichannel (not omnichannel) efforts reached new heights
• Getting to OCE at scale remains “the cake”; new trends like AI, hyperpersonalization,… are just “cherries” as long as
the foundation/cake is not in place
2. However, the gap with how physicians want to engage with biopharma is growing further – while F2F access
is going down again…”make every moment matter” – also new role for marketing & medical – the “war for
attention” is on.
3. Prescriber satisfaction with biopharma’s OCE launch efforts is even lower than their average satisfaction
levels, while successful launches are increasingly rare
4. Despite pharma’s lower urgency overall ( see 1), some companies and brands continue to accelerate their OC
investments – external benchmarking is an important driver for long-term customer leadership and for
keeping the momentum in the transition
5. Omnichannel does not stop at the prescriber level…also payers are keen on OCE engagement with biopharma
• There is a clear opportunity to look at the omnistakeholder level – across all functions: commercial, medical, access,
and patient service
Did any expert ever say that OCE was easy? OCE leadership is a marathon
Watch the full webinar here

8. Proprietary and confidential information
© Across Health
8
25/04/2023
There’s more where this came from: see our brandnew GLOBAL TRENDS REPORT!
across.health/GlobalTrendsReport
Download for free NOW!

9. Proprietary and confidential information
© Across Health
9
25/04/2023
Proprietary and confidential information
© Across Health 9
25/04/2023
FEB to SEP 2023
Want to know more? Join us on our upcoming webinars
• ‘Omnichannel myopia’ in the post-Covid era:
The importance of Cx Benchmarking
THURSDAY, MAR. 23TH 16H CET
• Omnichannel Launch Excellence:
From global to local
TUESDAY, JUN. 13TH 16H CET
• Omnichannel maturity:
What’s the industry up to (Maturometer™ 2023)?
TUESDAY, SEPT. 26TH 16H CET
All our resources at your fingertips:
https://across.health/resources
To sign up:
across.health/2023-webinars

10. Proprietary and confidential information
© Across Health
10
25/04/2023
Proprietary and confidential information
© Across Health 10
25/04/2023
Thank you!
For more info,
contact us!
Watch the recorded webinar and
access the full deck here.